Suppr超能文献

用于传染病检测的分子方法和平台:FDA 批准和清除的检测方法综述。

Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.

机构信息

Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.

出版信息

J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25.

Abstract

The superior sensitivity and specificity associated with the use of molecular assays has greatly improved the field of infectious disease diagnostics by providing clinicians with results that are both accurate and rapidly obtained. Herein, we review molecularly based infectious disease diagnostic tests that are Food and Drug Administration approved or cleared and commercially available in the United States as of December 31, 2010. We describe specific assays and their performance, as stated in the Food and Drug Administration's Summary of Safety and Effectiveness Data or the Office of In Vitro Diagnostic Device Evaluation and Safety's decision summaries, product inserts, or peer-reviewed literature. We summarize indications for testing, limitations, and challenges related to implementation in a clinical laboratory setting for a wide variety of common pathogens. The information presented in this review will be particularly useful for laboratories that plan to implement or expand their molecular offerings in the near term.

摘要

分子检测的高灵敏度和特异性极大地提高了传染病诊断领域的水平,为临床医生提供了准确、快速的检测结果。本文回顾了截至 2010 年 12 月 31 日,美国食品药品监督管理局(FDA)批准或通过的、商业化的基于分子的传染病诊断检测方法。我们描述了特定的检测方法及其性能,依据来自 FDA 的安全性和有效性数据概要,或体外诊断设备评估和安全办公室的决策总结、产品说明书,或同行评议文献。我们总结了针对各种常见病原体的检测指征、局限性和在临床实验室实施的相关挑战。本文所提供的信息对那些计划在近期内实施或扩展其分子检测的实验室尤其有用。

相似文献

1
Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.
J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25.
3
Validation of laboratory-developed molecular assays for infectious diseases.
Clin Microbiol Rev. 2010 Jul;23(3):550-76. doi: 10.1128/CMR.00074-09.
4
Rapid diagnostic tests for infectious diseases in the emergency department.
Clin Microbiol Infect. 2021 Feb;27(2):182-191. doi: 10.1016/j.cmi.2020.02.024. Epub 2020 Feb 29.
5
FDA perspectives on diagnostic device clinical studies for respiratory infections.
Clin Infect Dis. 2011 May;52 Suppl 4(Suppl 4):S305-11. doi: 10.1093/cid/cir056.
6
A review of the FDA-approved molecular testing platforms for human papillomavirus.
J Am Soc Cytopathol. 2019 Sep-Oct;8(5):284-292. doi: 10.1016/j.jasc.2019.06.001. Epub 2019 Jun 13.
7
Companion and complementary diagnostics for infectious diseases.
Expert Rev Mol Diagn. 2020 Jun;20(6):619-636. doi: 10.1080/14737159.2020.1724784. Epub 2020 Feb 13.
8
Role of molecular diagnostics in the management of infectious disease emergencies.
Med Clin North Am. 2012 Nov;96(6):1067-78. doi: 10.1016/j.mcna.2012.08.005. Epub 2012 Sep 27.

引用本文的文献

1
A De Novo Luciferase Bioconjugate for the Cas13-Based Detection of Influenza A.
JACS Au. 2025 Jul 28;5(8):3914-3925. doi: 10.1021/jacsau.5c00576. eCollection 2025 Aug 25.
2
Rapid Amplification and Detection of Single-Stranded Nucleic Acids for Point-of-Care Diagnosis.
Small Methods. 2025 Jun;9(6):e2401733. doi: 10.1002/smtd.202401733. Epub 2025 Jan 6.
3
FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.
PLoS Negl Trop Dis. 2024 May 9;18(5):e0012116. doi: 10.1371/journal.pntd.0012116. eCollection 2024 May.
4
Clinical Applications of Quantitative Real-Time PCR in Virology.
Methods Microbiol. 2015;42:161-197. doi: 10.1016/bs.mim.2015.04.005. Epub 2015 Jul 7.
5
Bioluminescent Intercalating Dyes for Ratiometric Nucleic Acid Detection.
ACS Chem Biol. 2024 Feb 16;19(2):575-583. doi: 10.1021/acschembio.3c00755. Epub 2024 Feb 5.
6
S9.6-based hybrid capture immunoassay for pathogen detection.
Sci Rep. 2023 Dec 19;13(1):22562. doi: 10.1038/s41598-023-49881-w.
7
CRISPR‑based diagnostic approaches: Implications for rapid management of future pandemics (Review).
Mol Med Rep. 2023 Jun;27(6). doi: 10.3892/mmr.2023.13005. Epub 2023 May 5.
9
Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants.
Nat Biomed Eng. 2022 Aug;6(8):932-943. doi: 10.1038/s41551-022-00889-z. Epub 2022 May 30.
10
Consolidating and Upscaling Molecular Research Capacity in Nigeria: On Who's Account?
Front Res Metr Anal. 2022 Jan 5;6:788673. doi: 10.3389/frma.2021.788673. eCollection 2021.

本文引用的文献

3
Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach.
J Clin Virol. 2010 Sep;49(1):41-6. doi: 10.1016/j.jcv.2010.06.004. Epub 2010 Jul 15.
4
Validation of laboratory-developed molecular assays for infectious diseases.
Clin Microbiol Rev. 2010 Jul;23(3):550-76. doi: 10.1128/CMR.00074-09.
5
Performance of the Aptima HIV-1 RNA qualitative assay with 16- and 32-member specimen pools.
J Clin Microbiol. 2010 Sep;48(9):3343-5. doi: 10.1128/JCM.01030-10. Epub 2010 Jun 30.
8
Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C.
Aliment Pharmacol Ther. 2010 Jun;31(12):1251-67. doi: 10.1111/j.1365-2036.2010.04300.x. Epub 2010 Mar 17.
10
ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv. doi: 10.3310/hta13510.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验